TFX Teleflex Incorporated
XNYS 133.10 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TFX
$133.10
—
Key stats
$133.10
- 52-Week Range
- $100.18 – $145.00
- YTD
- +8.74%
- IV Rank (30D)
- 77.63
- Straddle Price
- $15.65
- P/C Vol Ratio
- 1.42
- Market Cap
- $5.5B
- Open
- $132.30
- Day Range
- $131.26 – $133.59
- Volume
- 92,873
- Prev Close
- $130.40
Fair Value
MODEL: NEUTRAL
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.61% (VRP-adj) |
| WACC | 8.30% |
| Volatility Risk Premium | +32.3pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.3B |
| Return on Equity (TTM) | -10.9% |
| Book / Price | 53.3% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 53.1% |
| FCF Margin (TTM) | 15.1% |
| Debt / Equity | 0.82 |
| Quality Score | 3/6 — normal (10y DCF) |
| Market-Implied Growth | +7.3% (reverse-DCF on current price) |
| SMA 50 | $130.89 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $125.91 |
| Bollinger Width / SMA20 | 7.1% (drives anchor stability) |
| Net Debt | $2.2B |
| Market Cap | $6B |
Peers used for multiples: ABT, EW, MDT, MMSI, SYK, ZBH
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
14%
20-Day Fair Value
≈ by Nov 20, 2026
$134.45
α +0.9%
rank 31%
conviction
56%
40-Day Fair Value
≈ by Dec 21, 2026
$135.75
α +1.9%
rank 24%
conviction
59%
60-Day Fair Value
≈ by Jan 19, 2027
$133.71
α +0.4%
rank 23%
conviction
14%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $13.54 | 20% | |
| DDM (Gordon) | $6.24 | 0% | |
| Peer P/E | n/a | 0% | median 32.0× · 6 peers |
| Peer EV/EBITDA | $151.61 | 6% | median 18.2× · 6 peers |
| Peer P/B | $233.14 | 8% | median 3.4× · 6 peers |
| Peer P/S | $183.36 | 8% | median 3.6× · 6 peers |
| Market Anchor (SMA50) | $130.89 | 40% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $129.26 | 18% | 18 strikes · skew -0.33 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNYS
- Market Cap
- $5.5B
- Employees
- 15,500
- List Date
- 1972-06-01
- CIK
- 0000096943
- Next Earnings
- 2026-11-05 (Pre-Market)
- EPS Forecast
- $1.92 (3 est.)
- Headquarters
- Wayne, PA
- Homepage
- https://www.teleflex.com
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology …
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -6.33% | -7.33% | -2.57% | -3.04% | 0.66% | -14.73% | -5.56% |
| Feb | 4.95% | 8.66% | -4.78% | -10.04% | -24.19% | 18.09% | -1.22% |
| Mar | 2.92% | 6.48% | 8.41% | 1.42% | 2.26% | -2.70% | 3.13% |
| Apr | 2.01% | -19.50% | 8.21% | -6.34% | -2.32% | 4.64% | -2.22% |
| May | -3.59% | 1.84% | -14.36% | -1.17% | -2.86% | 5.64% | -2.42% |
| Jun | 2.38% | -13.08% | 3.53% | -2.14% | -1.09% | -0.63% | -1.84% |
| Jul | -2.31% | -5.74% | 5.21% | 4.48% | -1.91% | 5.80% | 0.92% |
| Aug | 1.07% | -7.76% | -14.66% | 3.91% | 9.08% | 1.68% | -1.11% |
| Sep | -5.28% | -11.11% | -8.03% | 1.01% | -3.68% | -10.99% | -6.35% |
| Oct | -6.87% | 2.91% | -5.69% | -17.98% | 0.44% | 5.65%* | -3.59% |
| Nov | -17.21% | 6.79% | 20.36% | -8.69% | -6.86% | -- | -1.12% |
| Dec | 13.47% | 1.97% | 9.52% | -8.40% | 6.67% | -- | 4.65% |
| Total | -16.65% | -33.83% | -0.94% | -39.72% | -24.68% | 8.88% | -17.82% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $126.57
SMA 50: $130.83
SMA 200: $124.30
Current: $133.24
EMA 12: $128.68
EMA 26: $128.23
MACD: 0.4505 | Signal: 1.2235
BEARISH
ADX (14): 25.36
TREND
+DI: 22.26
−DI: 12.67
Momentum Oscillators
RSI (14): 62.02
NEUTRAL
Stoch %K: 90.53
Stoch %D: 88.06
Williams %R: -3.08
Volume & Volatility
BB Upper: $132.40
BB Lower: $120.73
OVERBOUGHT
OBV: -12,294,847
Vol SMA 20: 723,870
Vol ROC: -90.73%
ATR: $3.35
True Range: $3.19
HV 20: 25.5%
HV 30: 24.6%
HV 60: 26.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis
LLM Stock Analysis Report - TFX
Executive Summary
Overall Assessment: NEUTRAL (confidence level: 6/10)
Key Drivers:
- Positive earnings beats and FDA approvals driving stock price upward
- Low volatility and stable trend indicators suggest a range-bound market
Primary Risks:
- Regulatory issues or negative news sentiment could impact stock performance
- Options market pricing suggests potential for increased volatility ahead
Investment Thesis: TFX has demonstrated a strong uptrend, driven by positive earnings beats and FDA approvals. The options market is currently priced to reflect a relatively stable price environment, but there are signs of increased volatility ahead. As such, I recommend a neutral approach, monitoring key levels and catalysts for potential trading opportunities.
Recent News Sentiment Impact: The recent news headlines have been predominantly positive, with the FDA license for the first-ever freeze-dried plasma product driving sentiment upward. This positive news has contributed to the stock's current uptrend.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Range-bound
- Long-term (3-12 months): Uptrend
Support/Resistance Levels: The stock is currently trading above its 20-period SMA, indicating a strong uptrend. The upper Bollinger Band serves as resistance at $139.82.
Momentum Signals:
- RSI interpretation: Neutral (55.19)
- MACD signal: Bullish
- Bollinger Bands position: Squeeze
Volume Analysis: The stock has seen increased volume in recent weeks, suggesting institutional interest and a potentially higher volatility environment ahead.
News & Sentiment Analysis
Recent Headlines Summary:
- FDA licenses first-ever freeze-dried plasma product (positive)
- Teleflex Investors to Put a Lost Decade Behind (positive)
- Options market signals potential for increased volatility ahead
Sentiment Assessment: The sentiment is currently positive, driven by the FDA approval and strong earnings beats.
Catalyst Identification: Upcoming earnings dates could drive stock price movements.
Market Narrative: The news headlines are aligning with the technical signals, suggesting a strong uptrend ahead. However, there are signs of increased volatility ahead, which may impact the stock's performance.
Risk & Volatility Assessment
Risk Interpretation: Beta: 0.77 (low risk relative to market)
Volatility Regime: The stock is currently trading in a low-volatility regime, with historical volatility levels at 25.8% (HV20) and 30.7% (HV30).
Options Market Signals:
- IV rank: Low
- Put/call ratios: Neutral sentiment
Downside Protection: The lower Bollinger Band serves as support at $129.99.
Market Context & Positioning
Sector Performance: TFX is outperforming the sector, with a relative strength index of 0.24.
Institutional Activity: Increased volume and open interest suggest institutional interest in the stock.
Correlation Analysis: The stock has a low correlation coefficient (0.24) compared to the market, indicating potential for independent price movements.
Relative Valuation: TFX is trading near its upper Bollinger Band, suggesting a relatively high valuation.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $139.82 (upper Bollinger Band)
- Support: $129.99 (lower Bollinger Band)
Breakout/Breakdown Levels:
- Potential breakout above $140.00
- Potential breakdown below $130.00
Time-Sensitive Catalysts: Earnings dates and FDA approvals could drive stock price movements.
Risk Management: Stop-loss levels and position sizing considerations should be adjusted to reflect the potential for increased volatility ahead.
Please let me know if you would like me to revise anything or provide further analysis.
Generated
News
All TFX news →
Earnings History
15 of 24 under expected move
Avg Expected Move
7.62%
Avg Actual Move
6.98%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-25 | Pre-Market | 5.87% | 0.52% | 0.09x | Within |
| 2021-04-29 | Pre-Market | 5.61% | 6.00% | 1.07x | Exceeded |
| 2021-07-29 | Pre-Market | 7.06% | 0.81% | 0.11x | Within |
| 2021-10-28 | Pre-Market | 7.29% | 5.16% | 0.71x | Within |
| 2022-02-24 | Pre-Market | 5.42% | 4.87% | 0.90x | Within |
| 2022-04-28 | Pre-Market | 12.75% | 6.54% | 0.51x | Within |
| 2022-07-28 | Pre-Market | 3.71% | 7.82% | 2.11x | Exceeded |
| 2022-10-27 | Pre-Market | 10.72% | 1.63% | 0.15x | Within |
| 2023-02-23 | Pre-Market | 0.75% | 2.07% | 2.76x | Exceeded |
| 2023-05-04 | Pre-Market | 6.57% | 8.53% | 1.30x | Exceeded |
| 2023-08-03 | Pre-Market | 7.60% | 3.68% | 0.48x | Within |
| 2023-11-02 | Pre-Market | 6.27% | 11.56% | 1.84x | Exceeded |
| 2024-02-22 | Pre-Market | 7.63% | 5.28% | 0.69x | Within |
| 2024-05-02 | Pre-Market | 6.31% | 6.06% | 0.96x | Within |
| 2024-08-01 | Pre-Market | 8.37% | 6.80% | 0.81x | Within |
| 2024-10-31 | Pre-Market | 7.35% | 14.52% | 1.98x | Exceeded |
| 2025-02-27 | Pre-Market | 8.94% | 21.69% | 2.43x | Exceeded |
| 2025-05-01 | Pre-Market | 9.36% | 8.16% | 0.87x | Within |
| 2025-07-31 | Pre-Market | 8.34% | 4.91% | 0.59x | Within |
| 2025-11-06 | Pre-Market | 12.71% | 13.02% | 1.02x | Exceeded |
| 2026-01-08 | Pre-Market | 5.08% | 13.06% | 2.57x | Exceeded |
| 2026-02-26 | Pre-Market | 9.54% | 6.37% | 0.67x | Within |
| 2026-05-07 | Pre-Market | 8.93% | 6.86% | 0.77x | Within |
| 2026-08-06 | Pre-Market | 10.64% | 1.54% | 0.14x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
TFX Options Activity & IV Rank
TFX IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 51.3%
7-DTE IV: —
Expected Move: $15.65
7-DTE Move: $15.65
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 12
Put Volume: 17
P/C Volume: 1.417
BEARISH
Call OI: 201
Put OI: 6
P/C OI: 0.03
Total OI: 207
ATM Options Pricing
ATM Call: $7.05
ATM Put: $8.60
Call %: 5.3%
Put %: 6.5%
Chain Summary
Chain Volume: 163
Chain OI: 304
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 85th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
85%
vs own history
GEX tilt
+1.00
OI-weighted, today
Vanna tilt
+0.64
δ-sensitivity to IV
Charm tilt
-0.73
δ-decay vs time
Vanna tilt +0.64: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.73: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 5 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
ATM 51.2% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)77.6HighOct 22
Straddle Price (30 DTE)$15.65Oct 22
Beta Analysis
Risk Metrics
Beta: 0.6369
Alpha: -0.88%
Correlation: 0.2056
R-Squared: 4.2%
Stock Volatility: 39.5%
Market Volatility: 12.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TFX
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $182.8M | #165 of 3716 | +111.4% | 13F | |
| Baupost Group Hedge fund Seth Klarman | $178.6M | #11 of 23 | -11.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $144.6M | #286 of 6285 | -2.6% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $9.6M | #1074 of 3138 | +33.5% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $132K | #2828 of 4729 | -8.7% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TFX Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 44,387,500 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$4.53M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.77M | 39.21% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.77M | 39.21% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $722.53K | 15.96% | 2026-06-30 |
| 4 | Wolverine Trading, LLC Custodian | $241.30K | 5.33% | 2025-09-30 |
| 5 | Simplex Trading, LLC Custodian | $12.68K | 0.28% | 2026-06-30 |
3 filers$2.42M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.91M | 79.06% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $367.60K | 15.18% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $139.44K | 5.76% | 2026-06-30 |
TFX Insider Trading (Form 4)
Latest: 2026-09-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | Sean Salmon | Director | Award (A) | +674 | — | EDGAR | |
| 2026-06-09 | Stuart A Randle | Director | Mixed | +1,604 | $129.84 | -$526.4K | EDGAR |
| 2026-06-09 | Jason R. Weidman | President and CEO | Award (A) | +53,983 | — | EDGAR | |
| 2026-05-19 | Neena M Patil | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-19 | Michael J Tokich | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-19 | Candace H Duncan | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-19 | Gretchen R Haggerty | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-19 | Andrew A Krakauer | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-19 | Jaewon Ryu | Director | Award (A) | +1,090 | — | EDGAR | |
| 2026-05-12 | Stuart A Randle | Interim President and CEO | Tax (F) | −289 | $133.06 | -$38.5K | EDGAR |
| 2026-03-05 | James Winters | Corp VP, Mfg and Supply | Mixed | +12,760 | $119.18 | -$29.4K | EDGAR |
| 2026-03-05 | Cameron P Hicks | Corp. VP & Chief HR Officer | Mixed | +7,998 | $119.18 | -$11.7K | EDGAR |
| 2026-03-05 | John Deren | Executive Vice President & CFO | Mixed | +13,555 | $119.18 | -$27.3K | EDGAR |
| 2026-03-05 | Daniel V. Logue | CVP, General Counsel & Secty | Mixed | +9,722 | $119.18 | -$15.6K | EDGAR |
| 2026-03-03 | James Winters | Corp VP, Mfg and Supply | Tax (F) | −661 | $122.06 | -$80.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TFX Insider Holdings
18 insiders · @ $133.24
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Liam Kelly | Chairman, President & CEO | 64,583 | $8.61M | -$17.23M | 48 | 2025-08-07 |
| 2 | Jason R. Weidman | President and CEO | 53,983 | $7.19M | $0 | 1 | 2026-06-09 |
| 3 | Daniel V. Logue | CVP, General Counsel & Secty | 25,089 | $3.34M | $0 | 15 | 2026-03-05 |
| 4 | Thomas E Powell | Executive Vice President & CFO | 21,210 | $2.83M | -$40.13M | 54 | 2025-04-03 |
| 5 | John Deren | Executive Vice President & CFO | 18,306 | $2.44M | -$4.50M | 29 | 2026-03-05 |
| 6 | James Winters | Corp VP, Mfg and Supply | 17,760 | $2.37M | $0 | 16 | 2026-03-05 |
| 7 | Stephen K. M.D. Klasko | Director | 17,212 | $2.29M | -$4.22M | 59 | 2025-05-13 |
| 8 | Stuart A Randle | Interim President and CEO | 16,524 | $2.20M | -$6.63M | 36 | 2026-06-09 |
| 9 | Cameron P Hicks | Corp. VP & Chief HR Officer | 13,848 | $1.85M | -$9.77M | 36 | 2026-03-05 |
| 10 | Jay White | CVP & Pres, Global Commercial | 9,218 | $1.23M | $0 | 11 | 2025-03-06 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TFX Board & Officers
As of SEC filings through Sep 10, 2026Directors 11
- Stephen K. M.D. Klasko · since May 1, 2008
- Stuart A Randle · since May 1, 2009
- Candace H Duncan · since May 1, 2015
- Gretchen R Haggerty · since Sep 13, 2016
- Andrew A Krakauer · since Jan 1, 2018
- John C Heinmiller · since Jan 1, 2019
- Neena M Patil · since Apr 29, 2022
- Jaewon Ryu · since May 5, 2023
- Michael J Tokich · since May 15, 2026
- Jason R. Weidman · since Jun 8, 2026
- Sean Salmon · since Sep 8, 2026
Officers 6
- Jason R. Weidman · President and CEO · since Jun 8, 2026
- John Deren · Executive Vice President & CFO · listed since Feb 2026
- Dominik Michal Reterski · Corporate Vice President, QARA · since Apr 1, 2026
- Cameron P Hicks · Corp. VP & Chief HR Officer · listed since Mar 2021
- Daniel V. Logue · CVP, General Counsel & Secty · listed since Mar 2022
- James Winters · Corp VP, Mfg and Supply · listed since Mar 2021
Changes in the last 10 years (35)
| Sep 8, 2026 | Sean Salmon became a director |
| Jun 8, 2026 | Jason R. Weidman became a director |
| Jun 8, 2026 | Jason R. Weidman became President and CEO |
| May 15, 2026 | Michael J Tokich became a director |
| Apr 1, 2026 | Dominik Michal Reterski became Corporate Vice President, QARA |
| Feb 25, 2026 | John Deren listed as Executive Vice President & CFO (previously Corp. VP & CAO) in SEC filings |
| Jan 23, 2026 | The company announced the departure of Liam Kelly from the board in an SEC filing |
| Jan 15, 2026 | Stuart A Randle first listed as Interim President and CEO in an SEC filing |
| Jan 8, 2026 | The company announced the departure of Liam Kelly as Chairman, President & CEO in an SEC filing |
| Apr 3, 2025 | Thomas E Powell reported in an SEC filing no longer being Executive Vice President & CFO |
| May 5, 2023 | Jaewon Ryu became a director |
| Feb 28, 2023 | Jay White listed as CVP & Pres, Global Commercial (previously VP & Pres, Global Commercial) in SEC filings |
| Apr 29, 2022 | Neena M Patil became a director |
| Mar 2, 2022 | Daniel V. Logue listed as CVP, General Counsel & Secty (previously VP, General Counsel, Secretary) in SEC filings |
| Feb 21, 2022 | The company announced the departure of Richard A Packer from the board in an SEC filing |
| Aug 26, 2021 | John Deren listed as Corp. VP & CAO (previously VP & Chief Accounting Officer) in SEC filings |
| Mar 17, 2021 | Cameron P Hicks listed as Corp. VP & Chief HR Officer (previously Corp. VP, HR & Communications) in SEC filings |
| Mar 3, 2021 | Liam Kelly listed as Chairman, President & CEO (previously President & CEO) in SEC filings |
| Mar 3, 2021 | James Winters listed as Corp VP, Mfg and Supply (previously Vice President, Mfg and Supply) in SEC filings |
| Feb 23, 2021 | Jay White became VP & Pres, Global Commercial |
| Feb 8, 2021 | James J Leyden reported in an SEC filing no longer being VP, General Counsel, Secretary |
| Jan 29, 2021 | Daniel V. Logue became VP, General Counsel, Secretary |
| May 11, 2020 | Cameron P Hicks listed as Corp. VP, HR & Communications (previously Vice President, Global HR) in SEC filings |
| Feb 18, 2020 | Mario Wijker became Vice President, QARA |
| Feb 18, 2020 | James Winters became Vice President, Mfg and Supply |
| Feb 28, 2019 | Liam Kelly first listed as a director in an SEC filing |
| Feb 28, 2019 | Karen Boylan listed as VP, Global Strategic Projects (previously Vice President, Global RA/QA) in SEC filings |
| Jan 1, 2019 | John C Heinmiller became a director |
| Apr 4, 2018 | Benson Smith no longer listed as Chairman & CEO in SEC filings |
| Feb 27, 2018 | Liam Kelly listed as President & CEO (previously President & COO) in SEC filings |
| Jan 1, 2018 | Andrew A Krakauer became a director |
| May 5, 2017 | Richard A Packer became a director |
| May 5, 2017 | John Deren became VP & Chief Accounting Officer |
| Feb 28, 2017 | Liam Kelly listed as President & COO (previously EVP & Chief Operating Officer) in SEC filings |
| Jan 24, 2017 | Benson Smith listed as Chairman & CEO (previously Chairman, President and CEO) in SEC filings |
Not reported recently (9)
- Jay White · Last reported as CVP & Pres, Global Commercial in an SEC filing dated Mar 6, 2025
- George Babich Jr · Last reported as a director in an SEC filing dated May 4, 2022
- Mario Wijker · Last reported as Vice President, QARA in an SEC filing dated Feb 26, 2020
- Benson Smith · Last reported as a director in an SEC filing dated Feb 19, 2020
- Karen Boylan · Last reported as VP, Global Strategic Projects in an SEC filing dated Jun 21, 2019
- Thomas Anthony Kennedy · Last reported as Senior VP, Global Operations in an SEC filing dated Sep 20, 2018
- W Kim Foster · Last reported as a director in an SEC filing dated May 18, 2018
- Jeffrey A Graves · Last reported as a director in an SEC filing dated May 10, 2017
- Patricia C Barron · Last reported as a director in an SEC filing dated Feb 24, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TFX Proposed Insider Sales (Form 144)
Latest: 2024-08-16
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-08-16 | RANDLE STUART A | Director | 2,674 | $638.9K | 2024-08-16 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
| 2024-03-01 | Hicks Cameron P | Officer | 7,401 | $1.67M | 2024-03-01 | MORGAN STANLEY SMITH BARNEY LLC … | — | EDGAR |
| 2023-12-27 | LIAM KELLY | Officer, Director | 26,256 | $6.57M | 2023-12-27 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-11-29 | POWELL THOMAS E | Officer | 13,952 | $3.07M | 2023-11-29 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-05-10 | RANDLE STUART A | Director | 3,021 | $742.3K | 2023-05-10 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-06-02
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-06-02 | 0001193125-26-251951 | EDGAR |
| 2026-06-01 | 0001193125-26-249764 | EDGAR |
| 2026-05-27 | 0001193125-26-242184 | EDGAR |
| 2026-05-20 | 0000096943-26-000068 | EDGAR |
| 2026-05-07 | 0000096943-26-000048 | EDGAR |
| 2026-04-30 | 0000096943-26-000042 | EDGAR |
| 2026-03-27 | 0000096943-26-000036 | EDGAR |
| 2026-03-17 | 0000096943-26-000031 | EDGAR |
| 2026-02-26 | 0000096943-26-000011 | EDGAR |
| 2026-01-23 | 0000096943-26-000006 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-27 | 0000096943-26-000019 | EDGAR |
| 2025-02-28 | 0000096943-25-000031 | EDGAR |
| 2024-02-23 | 0000096943-24-000036 | EDGAR |
| 2023-02-23 | 0000096943-23-000024 | EDGAR |
| 2022-03-01 | 0000096943-22-000016 | EDGAR |
| 2021-02-25 | 0000096943-21-000013 | EDGAR |
| 2020-02-21 | 0000096943-20-000017 | EDGAR |
| 2019-02-21 | 0000096943-19-000021 | EDGAR |
| 2018-02-22 | 0000096943-18-000028 | EDGAR |
| 2017-02-23 | 0000096943-17-000014 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-05-07 | 0000096943-26-000050 | EDGAR |
| 2025-11-06 | 0000096943-25-000138 | EDGAR |
| 2025-07-31 | 0000096943-25-000115 | EDGAR |
| 2025-05-01 | 0000096943-25-000077 | EDGAR |
| 2024-10-31 | 0000096943-24-000148 | EDGAR |
| 2024-08-02 | 0000096943-24-000132 | EDGAR |
| 2024-05-03 | 0000096943-24-000072 | EDGAR |
| 2023-11-03 | 0000096943-23-000102 | EDGAR |
| 2023-08-03 | 0000096943-23-000090 | EDGAR |
| 2023-05-04 | 0000096943-23-000049 | EDGAR |
ETF Holders
105 ETFs hold TFX
25 shown · $1.18B total exposure · 0.14% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.32% | $331.1M | $103.1B | 2026-10-20 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $168.1M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.07% | $119.2M | — | 2026-09-30 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.12% | $77.6M | — | 2026-09-30 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.06% | $59.7M | — | 2026-09-30 |
| 6 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.32% | $50.5M | $15.7B | 2026-10-20 |
| 7 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.61% | $46.1M | $7.6B | 2026-10-20 |
| 8 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.13% | $45.2M | — | 2026-10-20 |
| 9 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.16% | $43.1M | — | 2026-10-20 |
| 10 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.61% | $29.0M | $4.7B | 2026-10-20 |
| 11 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.12% | $27.4M | — | 2026-05-31 |
| 12 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.74% | $26.0M | $3.5B | 2026-10-20 |
| 13 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.04% | $24.2M | $57.3B | 2026-10-20 |
| 14 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.31% | $18.8M | — | 2026-09-30 |
| 15 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.02% | $17.6M | — | 2026-10-20 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.08% | $16.9M | — | 2026-09-30 |
| 17 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.11% | $15.4M | — | 2026-05-31 |
| 18 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.02% | $12.9M | $84.5B | 2026-10-20 |
| 19 | VIOV Vanguard S&P Small-Cap 600 Value ETF | Vanguard | 0.59% | $10.9M | — | 2026-09-30 |
| 20 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.14% | $10.4M | — | 2026-10-20 |
| 21 | IWS iShares Russell Mid-Cap Value ETF | iShares (BlackRock) | 0.06% | $8.8M | $15.6B | 2026-10-20 |
| 22 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $7.5M | $97.4B | 2026-10-20 |
| 23 | FNDX Schwab Fundamental U.S. Large Company ETF | Nport | 0.02% | $5.7M | — | 2026-05-31 |
| 24 | JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | JPMorgan | 0.19% | $5.4M | $2.9B | 2026-10-21 |
| 25 | DCOR Dimensional US Core Equity 1 ETF | Dimensional | 0.01% | $5.1M | — | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-6.65
TTM Revenue
$2.24B
TTM Net Income
$-294.47M
TTM Op. Cash Flow
$316.61M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $548.26M | $-8.15M | $-0.18 | $49.02M |
| Q4 '25 | 2025-12-31 | $-401.87M | $-714.33M | $-15.98 | $152.21M |
| Q3 '25 | 2025-09-28 | $913.02M | $-408.89M | $-9.24 | $107.28M |
| Q2 '25 | 2025-06-29 | $780.89M | $122.58M | $2.77 | $8.09M |
| Q1 '25 | 2025-03-30 | $414.26M | $95.00M | $2.07 | $73.09M |
| Q4 '24 | 2024-12-31 | $795.41M | $-136.66M | $-2.89 | $202.47M |
| Q3 '24 | 2024-09-29 | $764.38M | $111.00M | $2.36 | $228.74M |
| Q2 '24 | 2024-06-30 | $749.69M | $80.04M | $1.69 | $93.55M |
| Q1 '24 | 2024-03-31 | $737.85M | $15.29M | $0.32 | $110.98M |
| Q4 '23 | 2023-12-31 | $773.91M | $31.11M | $0.65 | $138.86M |
| Q3 '23 | 2023-10-01 | $746.39M | $137.14M | $2.90 | $201.62M |
| Q2 '23 | 2023-07-02 | $743.26M | $111.33M | $2.35 | $86.10M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-07
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.92
P/S
2.64
EV/EBITDA
16.53
EV/Sales
3.62
ROE
-9.5%
ROA
-4.3%
Div Yield
1.08%
FCF Yield
5.35%
Debt/Equity
0.82
Current Ratio
—
Market Cap
$5.91B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.05M
SI % of Float
9.75%
Days to Cover
4.10
Short Vol Ratio
82.0%
Free Float
41.55M
Float %
98.1%
Short interest 2026-09-30 • Short volume 2026-10-21 • Float 2026-08-14